1. Bertrand de Poly

    0 Comments Related Articles

    1. Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Bertrand de Poly

    Bertrand de Poly

    Bertrand Le Conte de Poly is CEO and Founder of LLTech. Bertrand Le Conte de Poly launched the High Speed Internet Business of a major French ISP in 6 month: USD 10 M turnover in one year. He raised 3.5 M USD for LLTech and established major collaboration with research and health institutions (INSERM, Institut Curie, APHP Hôpitaux de Paris).He has a dual education with a MSC. In life sciences from Agro Paris Tech and MBA from HEC.

  3. Quotes

    1. It is hard to access private capital in France for early stage startups without a proof-of-concept completed. Access to grants for LLTech directly or access for grants from 3rd parties that use LLTech equipment have been greatly beneficial for moving our vision of digital pathology forward. For the future it would be beneficial to reduce the amount of paper work and the long process.
      In Optical Coherence Tomography Used $500M of Federally Funded Research Over The Past Decade: How was it Used, What was Accomplished, and What’s to Come?
    2. We are proud to launch this product, paving the way to a new generation of OCT system. We have tried the system on many types of tissues and small animals, pointing out the capabilities in various research areas such as biobanking, matrigels, small animals and embryos imaging, clinical research .
      In LLTech launches the ultra high resolution - micron level - 3D Light-CT scanner for research
    3. Light-CT technology leapfrogs all other coherence tomography approaches and product platforms in terms of laboratory, clinical and operational requirements,..."There is at present no device enabling real-time 3D imaging of biopsies, since current imaging techniques in pathology are destructive, two-dimensional and non-digital.
      In LLTech brings optical biopsies to operating theaters: Coherence tomography technique allows surgeons to see biopsy results in 3D and almost real-time.
    4. Today, up to 40% of women having breast cancer surgery must go through a second procedure to complete the surgery, to remove either the remaining parts of the tumor or the nodes chain...The morphological information from a Light-CT scanner could allow a distinction between normal or cancerous tissue structures to be made within minutes, during the initial surgical procedure. Then an evaluation of whether the procedure should continue or be stopped can be made.
      In LLTech brings optical biopsies to operating theaters: Coherence tomography technique allows surgeons to see biopsy results in 3D and almost real-time.